Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None202320222021202020192018201720162015 Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting 05/02/2022 Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference 04/28/2022 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 03/10/2022 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 03/01/2022 Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations 02/23/2022 Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy 02/22/2022 Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium 02/17/2022 Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 02/09/2022 Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 112
Year None202320222021202020192018201720162015 Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting 05/02/2022 Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference 04/28/2022 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 03/10/2022 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 03/01/2022 Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations 02/23/2022 Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy 02/22/2022 Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium 02/17/2022 Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 02/09/2022 Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 112
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting 05/02/2022
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 03/10/2022
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations 02/23/2022
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium 02/17/2022
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021